Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells

Experimental and Therapeutic Medicine

Volumn 7, Issue 6, 2014, Pages 1611-1616

  Huang, Fang ^a   Wu, Xiao Nan ^a   Chen, Jie ^a   Wang, Wen Xiang ^a   Lu, Zu Fu ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Human breast cancer doxorubicin resistant cell; Multidrug resistance; Resveratrol

Indexed keywords

DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; RESVERATROL;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DOSE RESPONSE; FLUORESCENCE SPECTROSCOPY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MTT ASSAY; MULTIDRUG RESISTANCE; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROFLUOROMETRY; WESTERN BLOTTING;

EID: 84898410785     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1662     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global Cancer Statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM and Dickson RB: Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 84: 1506-1512, 1992.
3. Robert J: Resistance to cytotoxic agents. Curr Opin Pharmacol 1:353-357, 2001.
4. Avendaño C and Menéndez JC: Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 9: 159-193, 2002.
5. Ross DD: Novel mechanisms of drug resistance in leukemia. Leukemia 14: 467-473, 2000.
6. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
7. Tan B, Piwnica-Worms D and Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450-458, 2000.
8. Mayer LD and Shabbits JA: The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev 20: 87-93, 2001.
9. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34: 378-390, 2008.
10. Zhu HJ, Wang JS, Guo QL, Jiang Y and Liu GQ: Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6. Biol Pharm Bull 28: 1974-1978, 2005.
11. Zhou J, Liu M, Aneja R, Chandra R, Lage H and Joshi HC: Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 66: 445-452, 2006.
12. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
13. Kundu JK and Surh YJ: Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 269: 243-261, 2008.
14. Goswami SK and Das DK: Resveratrol and chemoprevention. Cancer Lett 284: 1-6, 2009.
15. Bishayee A: Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila) 2: 409-418, 2009.
16. Huang F, Huang ZJ, Chen J and Wang JL: Studies of several polyphenolses on multidrug resistance to human breast carcinoma MCF-7/ADM Cell. J Pract Oncol 24: 121-123, 2009 (In Chinese).
17. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, et al: Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 44: 591-601, 2011.
18. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
19. Chambers SK, Hait WN, Kacinski BM, Keyes SR and Handschumacher RE: Enhancement of anthracycline growth inhibition in parent and multidrug resistant Chinese hamster ovary cells by cyclosporin A and its analogues. Cancer Res 49: 6275-6279, 1989.
20. Ganapathi R, Grabowski D, Rouse W and Riegler F: Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. Cancer Res 44: 5056-5061, 1984.
21. Marques FZ, Markus MA and Morris BJ: Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 41: 2125-2128, 2009.
22. Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, Centeno F, Alvarez-Barrientos A and Fernandez-Salguero PM: Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 115: 74-84, 2005.
23. Ben itez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM and Castellón EA: Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 28: 282-293, 2007.
24. Loo TW and Clarke DM. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 277: 44332-44338, 2002